Skip to main content

BIOMARCADORES CENTRALES Y PERIFERICOS DE RESPUESTA ANTIDEPRESIVA: ESTUDIO TRANSLACIONAL ENTRE PACIENTES CON TRASTORNO DEPRESIVO RESITENTE AL TRATAMIENTO Y MODELO DE DEPRESION EN RATA

PI18/00036

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2018
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION PARC TAULI
Execution centre CORPORACION SANITARIA PARC TAULI

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

The neurobiological basis of cognitive side effects of electroconvulsive therapy, a systematic review

  • Bassa, Adriana
  • Sagués, Teresa
  • Porta-Casteràs, Daniel|||0000-0002-3921-3607
  • Serra, Pilar
  • Martínez Amorós, Erika|||0000-0002-6718-7346
  • Palao, Diego|||0000-0002-3323-6568
  • Cano, Marta|||0000-0003-0675-9483
  • Cardoner, Narcís|||0000-0001-9633-0888
Decades of research have consistently demonstrated the efficacy of electroconvulsive therapy (ECT) for the treatment of major depressive disorder (MDD), but its clinical use remains somewhat restricted because of its cognitive side effects. The aim of this systematic review is to comprehensively summarize current evidence assessing potential biomarkers of ECT-related cognitive side effects. Based on our systematic search of human studies indexed in PubMed, Scopus, and Web of Knowledge, a total of 29 studies evaluating patients with MDD undergoing ECT were reviewed. Molecular biomarkers studies did not consistently identify concentration changes in plasma S-100 protein, neuron-specific enolase (NSE), or Aβ peptides significantly associated with cognitive performance after ECT. Importantly, these findings suggest that ECT-related cognitive side effects cannot be explained by mechanisms of neural cell damage. Notwithstanding, S-100b protein and Aβ40 peptide concentrations, as well as brain-derived neurotrophic factor (BDNF) polymorphisms, have been suggested as potential predictive biomarkers of cognitive dysfunction after ECT. In addition, recent advances in brain imaging have allowed us to identify ECT-induced volumetric and functional changes in several brain structures closely related to memory performance such as the hippocampus. We provide a preliminary framework to further evaluate neurobiological cognitive vulnerability profiles of patients with MDD treated with ECT.